Rayner’s Galaxy spiral IOL achieves nationwide reimbursement in Australia
Posted on 1/03/2026
Australian cataract patients can now gain broader access to next-generation lens technology, after Rayner secured Medical Device and Human Tissue Advisory Committee (MDHTAC) acceptance and Prostheses List (PL) reimbursement for RayOne Galaxy, effective 1 March 2026.
RayOne Galaxy is the world’s first spiral IOL, representing a significant advancement in premium lens replacement technology. Developed with AI, its unique non-diffractive spiral optic delivers a smooth and continuous full range of vision with minimised dysphotopsia and 0% loss of transmitted light.*
Since its global launch in January 2025, RayOne Galaxy has demonstrated strong international clinical adoption, with over 90,000 lenses shipped worldwide.
Surgeons across multiple international markets report consistent refractive predictability, broad functional visual range, and high patient satisfaction in everyday clinical practice. Real-world experience has been presented at leading international congresses, reinforcing confidence in the technology.
In parallel, a US clinical study conducted under an FDA-approved Investigational Device Exemption (IDE) confirmed favourable safety and effectiveness outcomes, with regulatory review in the United States ongoing.
Now, with PL reimbursement confirmed, privately insured cataract patients can access the Galaxy spiral lens without the additional out-of-pocket costs typically associated with non-listed lenses – an important step forward in expanding access to this advanced presbyopia-correcting technology.
Lisa Farquhar, Rayner’s Country Manager for Australia & New Zealand, said: “Galaxy was designed to redefine what’s possible – delivering a continuous range of vision without the trade-offs patients get with diffractive trifocal lenses. We are proud that this innovative technology will now be accessible to any privately insured patient in Australia, helping surgeons offer truly premium outcomes to more people than ever before.”
*Abela-Formanek C et al. Performance of the First Spiral Refractive Intraocular Lens for Continuous Full Range of Vision. J Refract Surg. 2025 Nov;41(11):e1213-e1222.
About Rayner:
Since the implantation of the first Rayner intraocular lens by Sir Harold Ridley in 1949, Rayner has had the goal to improve vision and restore sight worldwide. Today, Rayner’s mission remains to deliver innovative and clinically superior ophthalmic products that respond to the expectations of our global customers to improve the sight and quality of life of their patients.
Headquartered in Worthing, United Kingdom, Rayner markets its medical devices, pharmaceuticals, and digital solutions globally through a network of distributors and includes direct sales teams in the United Kingdom, Eire, USA, Canada, Brazil, India, Poland, Australia, Germany, Austria, Switzerland, France, Italy, Spain, and Portugal.
Not all Rayner products are approved for sale in every country. Please contact your local Rayner distributor for details of which products are available in your area.
©2026 Rayner Group, all rights reserved. Rayner, RayOne and Galaxy are proprietary marks of the Rayner Group. All other trademarks are property of their respective owners. Rayner, The Ridley Innovation Centre, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539 | EC 2026-20 EN